Professor Andrew Beggs FRCS (Gen), PhD

Andrew Beggs

Institute of Cancer and Genomic Sciences
Head of Section - Molecular Oncology, Pathology and Genetics, Professor in Surgery & Cancer Genetics
Head of West Midlands GI & Gynaecology Cancer Tumour Board
Cancer Research UK & RCSEng Advanced Clinician Scientist, Consultant Colorectal & General Surgeon

Contact details

Email
a.beggs@bham.ac.uk
View my research portal
Address
Institute of Cancer and Genomic Sciences
University of Birmingham
Vincent Drive
Birmingham
B15 2TT
UK

Andrew Beggs is a Professor of Cancer Genetics & Surgery in the Institute of Cancer and Genomic Sciences, University of Birmingham. He currently holds a Cancer Research UK & Royal College of Surgeons Advanced Clinician Scientist award. He is also an Consultant Colorectal & General  Surgeon at the Queen Elizabeth Hospital in Birmingham with a subspeciality interest in laparoscopic rectal cancer surgery and advanced endoscopy.

His major research interests include colorectal, oesophageal and sarcoma cancer biology and translational medicine. He has published articles in The Lancet, Gut, Journal of Pathology and PLoS Genetics. He collaborated in writing the European consensus guidelines for the management of Peutz-Jeghers syndrome.

Andrew has been awarded grant funding from Cancer Research UK, Medical Research Council, Wellcome Trust, Illumina UK, Cancer Research UK, Mason Medical Research Foundation, Peel Medical Research Trust & St Georges Hospital Charity.

His current research programme is examining the molecular genetics of colorectal cancer, and has recently received programme funding from CRUK to set up organoid model systems to understand neoadjuvant chemoradiosensitivity in rectal cancer.  He is also carrying out research into rare cancers using multi-omics profiling;  biomarker development technologies and runs a bioinformatics “dry-lab” to search for novel therapeutic targets and stratification markers.

For more information please look at the laboratory website .

We face two key factors when trying to save patients' lives; early diagnosis and matching the right drug to the individual patient. With help, Birmingham could develop a genetic test, to catch the early signs of bowel cancer before the patient themselves becomes aware of them. Find out how to support our research through the Birmingham in Action campaign.

Andrew has also been leading COVID-19 testing in re-purposed labs, enabling same-day PCR testing for staff at University Hospitals Birmingham NHS Foundation Trust, Birmingham Women’s and Children’s NHS Foundation Trust and the West Midlands Ambulance Service.

Qualifications

  • FRCS(Gen) – subspecialty training in Coloproctology 2016
  • PhD Cancer Genetics, 2012
  • MRCS (England), 2006
  • MBBS with distinction Medicine & Surgery, 2003
  • BSc(Hons) Radiological Sciences (i), 2000

Biography

Andrew qualified from Guy’s, Kings & St. Thomas’ Hospitals School of Medicine, Kings College London in 2003 with distinction, where he also completed a BSc in Radiological Sciences at Kings College London where he carried out research into the use of standardised uptake values (SUV) in 18-fluorodeoxyglucose and 11C-methionine Positron Emission Tomography (18FDG-PET) in quantifying malignant potential in tumours.

Andrew was an Anatomy Demonstrator at Guys Hospital, Kings College London, under supervision of Professor Harold Ellis & Professor Susan Standring (Editor of Grays Anatomy). He then undertook a Basic Surgical Training rotation at St Georges Hospital, London and Kingston Hospital, Surrey, being awarded the Membership of the Royal College of Surgeons in 2006.

Andrew started his doctoral research in 2007 when he was appointed a research registrar in Colorectal Surgery at Croydon University Hospital, undertaking research leading to the award of a PhD in the laboratory of Professor Ian Tomlinson at the London Research Institute  of Cancer Research UK, latterly at the University of Oxford. Andrew was also supervised by Professor Shirley Hodgson (St Georges, University of London) and Mr Muti Abulafi (Croydon University Hospital). Subsequent to his research, he was appointed to the higher surgical training scheme in South-West London and Surrey in 2010 as a Specialty Registrar in General Surgery.

He was then appointed as a deanery-funded Academic Clinical Lecturer (ACL) in General Surgery at the University of Birmingham/West Midlands Deanery where he undertook training in General Surgery and subspecialist training in Coloproctology. He was awarded a Wellcome Trust postdoctoral fellowship for Clinician Scientists and undertook work examining novel determinants of radiosensitivity in rectal cancer. He gained his Certificate of Completion of Specialist Training in General Surgery and Coloproctology in October 2016. He was appointed as Professor of Cancer Genetics and Surgery in 2020.

Teaching

Postgraduate supervision

Andrew has supervised multiple successful clinical and non-clinical PhD and MD projects at Birmingham. He is interested in supervising doctoral research students in the following areas:

  • Colorectal, oesophageal and sarcoma cancer genetics/biology
  • Cancer genetics in general
  • Next generation sequencing techniques
  • Cancer bioinformatics

Research

Basic science:

  • Epigenetics
  • Biomarkers
  • Colorectal cancer genetics
  • Colorectal cancer biology
  • Retroperitoneal Sarcoma
  • Genome association wide studies
  • Telomere biology & genome stability
  • DNA repair
  • Next generation sequencing
  • Microarrays (SNP, aCGH & methylation)
  • Bioinformatics

Clinical:

  • Rectal cancer
  • Pelvic floor dysfunction
  • Anal incontinence
  • Bedside ultrasound
  • Regression modelling & statistical analysis

Other activities

  • GMC Partner:  Andrew works for the General Medical Council appraising specialist and foundation training in surgery as well as curriculum approvals for surgical specialties
  • Deputy Chair of Junior Investigators Group, CRUK Experimental Cancer Medicine Centre Network 2012-2015
  • Scientific Director, College of Medical and Dental Sciences Genomics Facility (Genomics Birmingham)
  • Andrew is currently a reviewer for The Lancet, British Medical Journal, The Journal of Neurological Sciences, British Journal of Surgery, Genes Chromosomes & Cancers, Gastroenterology and PLoS ONE. He also acts as a peer reviewer for Cancer Research UK, the MRC, The CORE Charity, Big-C Cancer Research and Heart UK.
  • University enabling technologies committee GeCIP for 100KG colorectal

Publications

Recent publications

Article

Quraishi, MN, Acharjee, A, Beggs, AD, Horniblow, R, Tselepis, C, Gkoutos, G, Ghosh, S, Rossiter, A, Loman, N, van Schaik, W, Withers, D, Walters, JRF, Hirschfield, GM & Iqbal, TH 2020, 'A pilot integrative analysis of colonic gene expression, gut microbiota and immune infiltration in primary sclerosing cholangitis-inflammatory bowel disease: association of disease with bile acid pathways', Journal of Crohn's & Colitis. https://doi.org/10.1093/ecco-jcc/jjaa021

S:CORT Consortium 2020, 'Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning', Gut. https://doi.org/10.1136/gutjnl-2019-319866

Kwok, MCK, Oldreive, C, Rawstron, AC, Goel, A, Papatzikas, G, Jones, R, Drennan, S, Agathanggelou, A, Sharma-Oates, A, Evans, P, Smith, E, Dalal, S, Mao, J, Hollows, R, Gordon, N, Hamada, M, Davies, N, Parry, H, Beggs, A, Munir, T, Moreton, P, Paneesha, S, Pratt, G, Taylor, M, Forconi, F, Baird, D, Cazier, J-B, Moss, P, Hillmen, P & Stankovic, T 2020, 'Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL: natural history and mechanism of spontaneous CLL regression', Blood, vol. 135, no. 6, pp. 411-428. https://doi.org/10.1182/blood.2019001262

Schwenzer, H, Abdel Mouti, M, Neubert, P, Morris, J, Stockton, J, Bonham, S, Fellermeyer, M, Chettle, J, Fischer, R, Beggs, AD & Blagden, SP 2020, 'LARP1 isoform expression in human cancer cell lines', RNA biology. https://doi.org/10.1080/15476286.2020.1744320

OCCAMS Consortium & Beggs, A 2020, 'Machine learning to predict early recurrence after oesophageal cancer surgery', British Journal of Surgery. https://doi.org/10.1002/bjs.11461

Breeze, J, Bowley, DM, Combes, JG, Baden, J, Orr, L, Beggs, A, DuBose, J & Powers, DB 2020, 'Outcomes following penetrating neck injury during the Iraq and Afghanistan conflicts: A comparison of treatment at US and United Kingdom medical treatment facilities', The Journal of Trauma and Acute Care Surgery, vol. 88, no. 5, pp. 696-703. https://doi.org/10.1097/TA.0000000000002625

Bhangu, A, Nepogodiev, D, Rowland, N, Magill, L, Glasbey, J, Forde, C, Bisgaard, T, Handley, K, Mehta, S, Morton, D, Pinkney, T & Beggs, A 2020, 'Prophylactic biological mesh reinforcement versus standard closure of stoma site (ROCSS): a multicentre, randomised controlled trial', The Lancet, vol. 395, no. 10222, pp. 417-426. https://doi.org/10.1016/S0140-6736(19)32637-6

Bosworth, A, Whalley, C, Poxon, C, Wanigasooriya, K, Pickles, O, Aldera, EL, Papakonstantinou, D, Morley, GL, Walker, EM, Zielinska, AE, McLoughlin, D, Webster, C, Plant, T, Ellis, A, Richter, A, Kidd, IM & Beggs, AD 2020, 'Rapid implementation and validation of a cold-chain free SARS-CoV-2 diagnostic testing workflow to support surge capacity', Journal of Clinical Virology, vol. 128, 104469. https://doi.org/10.1016/j.jcv.2020.104469

Stockton, JD, Nieto, T, Wroe, E, Poles, A, Inston, N, Briggs, D & Beggs, AD 2020, 'Rapid, highly accurate and cost-effective open-source simultaneous complete HLA typing and phasing of class I and II alleles using nanopore sequencing', HLA, vol. 96, no. 2, pp. 163-178. https://doi.org/10.1111/tan.13926

Breeze, J, Bowley, DM, Harrisson, SE, Dye, J, Neal, C, Bell, RS, Armonda, RA, Beggs, AD, DuBose, J, Rickard, RF & Powers, DB 2020, 'Survival after traumatic brain injury improves with deployment of neurosurgeons: a comparison of US and UK military treatment facilities during the Iraq and Afghanistan conflicts', Journal of Neurology Neurosurgery and Psychiatry, vol. 91, no. 4, pp. 359-365. https://doi.org/10.1136/jnnp-2019-321723

Pestinger, V, Smith, M, Sillo, T, Findlay, JM, Laes, J-F, Martin, G, Middleton, G, Taniere, P & Beggs, AD 2020, 'Use of an integrated pan-cancer oncology enrichment next-generation sequencing assay to measure tumour mutational burden and detect clinically actionable variants', Molecular Diagnosis and Therapy, vol. 24, no. 3, pp. 339-349. https://doi.org/10.1007/s40291-020-00462-x

Brooks, J, Antao Mobre De Menezes, ARE, Ibrahim, M, Archer, L, Lal, N, Bagnall, C, Zeidler, SVV, Valentine, H, Spruce, R, Batis, N, Bryant, J, Hartley, M, Kaul, B, Ryan, G, Bao, R, Khattri, A, Lee, S, Ogbureke, KUE, Middleton, G, Tennant, D, Beggs, A, Deeks, J, West, CML, Cazier, J-B, Willcox, B, Seiwert, TY & Mehanna, H 2019, 'Development and validation of a combined hypoxia and immune prognostic classifier for head and neck cancer', Clinical Cancer Research, vol. 25, no. 17, pp. 5315-5328. https://doi.org/10.1158/1078-0432.CCR-18-3314

Kleeman, SO, Koelzer, VH, Jones, HJ, Vazquez, EG, Davis, H, East, JE, Arnold, R, Koppens, MA, Blake, A, Domingo, E, Cunningham, C, Beggs, AD, Pestinger, V, Loughrey, MB, Wang, L-M, Lannagan, TR, Woods, SL, Worthley, D, Consortium, SC, Tomlinson, I, Dunne, PD, Maughan, T & Leedham, SJ 2019, 'Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification', Gut. https://doi.org/10.1136/gutjnl-2019-319126

Review article

Tyler, R, Wanigasooriya, K, Taniere, P, Almond, M, Ford, S, Desai, A & Beggs, A 2020, 'A review of retroperitoneal liposarcoma genomics', Cancer Treatment Reviews, vol. 86, 102013. https://doi.org/10.1016/j.ctrv.2020.102013

Wanigasooriya, K, Tyler, R, Barros-Silva, JD, Sinha, Y, Ismail, T & Beggs, AD 2020, 'Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors', Cancers, vol. 12, no. 5, 1278. https://doi.org/10.3390/cancers12051278

View all publications in research portal